The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease (SWITCH)
This study has been completed.
University of Rostock
First Posted: December 29, 2010
Last Update Posted: April 13, 2016
Information provided by (Responsible Party):
Prof. Dr. Arndt Rolfs, University of Rostock